Staphylococcus Aureus and Methicillin-Resistant Staphylococcus Aureus Nucleic Acid Detection Kit (Fluorescence PCR)

Intended Use

This kit is designed for the in vitro qualitative detection of nucleic acids from Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in human samples, including sputum, nasal swabs, and specimens from skin and soft tissue infections. When testing sputum and nasal swabs, it is used in healthcare facilities for the prevention and control of MRSA nosocomial infections among hospitalized patients, such as those in intensive care, surgical, and long-term care units. The assay may also aid in the auxiliary diagnosis of patients suspected of having respiratory infections caused by SA or MRSA. Additionally, when combined with other laboratory methods (e.g., microbial culture), it can support the diagnosis of MRSA/SA skin and soft tissue infections. Results are not intended for direct use in guiding antibiotic therapy.

Epidemiology

Staphylococcus aureus is a significant nosocomial pathogen. It is a Gram-positive bacterium belonging to the Staphylococcus genus, capable of producing various toxins and invasive enzymes, and is known for its widespread distribution, high pathogenicity, and elevated resistance rates. The thermostable nuclease gene (nuc) is highly conserved in S. aureus.

In recent years, the extensive use of hormones and immunomodulatory drugs, combined with the overuse of broad-spectrum antibiotics, has led to an increase in healthcare-associated infections caused by methicillin-resistant S. aureus (MRSA) within staphylococci. In China, the national average MRSA detection rate reached 30.2% in 2019. MRSA is categorized into healthcare-associated (HA-MRSA), community-associated (CA-MRSA), and livestock-associated (LA-MRSA) strains. These groups show substantial differences in microbiology, antimicrobial resistance patterns (for example, HA-MRSA typically exhibits greater multidrug resistance than CA-MRSA), and clinical features such as infection site. These characteristics can be used to differentiate CA-MRSA from HA-MRSA, although the distinctions are blurring due to continuous population movement between healthcare and community settings. MRSA is multidrug resistant, demonstrating resistance not only to β-lactam antibiotics but also, to varying extents, to aminoglycosides, macrolides, tetracyclines, and quinolones. Resistance rates vary considerably by region and are changing over time. MRSA can enter the body via skin breaks, hair follicles, or the bloodstream, causing suppurative infections; individuals with skin disorders or burns are particularly vulnerable. Pneumonia is among the most frequent clinical presentations of MRSA infection, and inadequate treatment contributes significantly to high mortality.